The ROCKET AF (Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial [105] examined the efficacy and safety of rivaroxaban vs. warfarin in DM subjects with atrial fibrillation (AF). Here, F10 is linked to atrial fibrillation.